Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 1, 2015, Pages 61-68

  Aida, Yuta ^a   Abe, Hiroshi ^a   Tomita, Yoichi ^a   Nagano, Tomohisa ^a   Seki, Nobuyoshi ^a   Sugita, Tomonori ^a   Itagaki, Munenori ^a   Ishiguro, Haruya ^a   Sutoh, Satoshi ^a   Aizawa, Yoshio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen IV; FIB 4; Hepatitis C virus; Liver fibrosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; COLLAGEN TYPE 4; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; HYALURONIC ACID; TRIACYLGLYCEROL; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; AREA UNDER THE CURVE; BLOOD; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; RECEIVER OPERATING CHARACTERISTIC; SEROLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BIOMARKERS; COLLAGEN TYPE IV; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84924130255     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.yad     Document Type: Article

References (31)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643. doi:10.1038/35007508
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
3. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793. doi:10.1111/j.1440-1746.2007.05042.x
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285. doi:10.1111/j.1365-2036.2011.04724.x
5. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26. doi:10.1055/s-2001-12926
6. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140. doi:10.1053/gast.2002.34168
7. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-427. doi:10.1053/jhep.2003.50320
8. Seko Y, Sumida Y, Tanaka S, et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven nonalcoholic fatty liver disease. Hepatol Res 2014. doi:10.1111/hepr.12407
9. Sakugawa H, Nakasone H, Nakayoshi T, et al. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. Hepatogastroenterology 2003; 50: 2005-2008.
10. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J. Gastroenterol 2003; 38: 954-961. doi:10.1007/s00535-003-1178-8
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474. doi:10.1016/s0002-9270(99)00433-5
12. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419. doi:10.1016/s0016-5085(99)70506-8
13. Kleiner DE, Brunt EM, Van Natta, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. doi:10.1002/hep.20701
14. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906. doi:10.1053/j.gastro.2005.03.084
15. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880. doi:10.1002/hep.21346
16. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60: 832-843. doi:10.1002/hep.27296
17. Nishie A, Asayama Y, Ishigami K, et al. MR prediction of liver fibrosis using a liver-specific contrast agent: superparamagnetic iron oxide versus Gd-EOB-DTPA. J Magn Reson Imaging 2012; 36: 664-671. doi:10.1002/jmri.23691
18. Santos VN, Leite-Mór MM, Kondo M, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005; 38: 747-753. doi:10.1590/s0100-879x2005000500012
19. Obata K, Iwata K, Ichida T, et al. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989; 181: 293-304. doi:10.1016/0009-8981(89)90235-0
20. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000; 32: 325-330. doi:10.1016/s0016-5085(98)85526-1
21. Ueno T, Inuzuka S, Torimura T, et al. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a onestep sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol 1992; 27: 513-520. doi:10.3109/00365529209000114
22. Muwaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996; 24: 148-154. doi:10.1016/s0168-8278(96)80023-7
23. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser 1980; 646: 1-80.
24. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325. doi:10.1002/hep.21178
25. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736. doi:10.1002/hep.24105
26. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832. doi:10.1016/s0140-6736(96)07642-8
27. Bedossa P, The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20. doi:10.1002/hep.1840200104
28. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factor for liver fibrosis. Hepatol Res 2002; 24: 429-438. doi:10.1016/s1386-6346(02)00246-2
29. Sand JM, Larsen L, Hogaboam C, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis–validation of two novel biomarker assays. PLoS ONE 2013; 8: e84934. doi:10.1371/journal.pone.0084934
30. Leeming DJ, Byrjalsen I, Jimenez W, Christiansen C, Karsdal MA. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis-a serological evaluation. Liver Int 2013; 33: 439-447. doi:10.1111/liv.12044
31. Leeming DJ, Nielsen MJ, Dai Y, et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 2012; 42: 482-493. doi:10.1111/j.1872-034x.2011.00946.x